Overview

Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients

Status:
Unknown status

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

to evaluate whether bone marker can provide the valuable predictor of skeletal complications and whether regular assessing of NTX(N-telopeptide of type I collagen) and osteocalcin can be useful in advanced breast cancer patients with bone metastasis receiving zoledronic acid.

Phase:

Phase 4

Details

Lead Sponsor:

Korean Breast Cancer Study Group

Treatments:

Diphosphonates
Zoledronic Acid